stockrowTakeda Pharmaceutical Co.
TAK Healthcare Drug Manufacturers Specialty & Generic
Takeda Pharmaceutical Co.’s revenue for fiscal 2026 (year ended March 2026) was $29.7 billion, down 1.66% from fiscal 2025.
- Revenue
- +1.71%
- EPS
- −4.35%
- Free cash flow
- +54.9%
- Total debt
- −7.28%
Quarter to September 2026, against a year earlier
Follow TAK
Alert me
Takeda Pharmaceutical Co. (TAK) EPS (diluted)
Takeda Pharmaceutical Co.'s EPS (diluted) for fiscal 2026 was −$0.32, compared with $0.22 in fiscal 2025. Over the twelve months to 30 June 2026 it was $0.66. Over the past ten years it has ranged from −$0.78 (fiscal 2015) to $1.13 (fiscal 2021); the current reading is higher than 17% of that period. EPS (diluted) has fallen for 3 consecutive fiscal years. Takeda Pharmaceutical Co. ranks 16th of 75 Drug Manufacturers Specialty & Generic companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2026 | −$0.32 | — |
| FY2025 | $0.22 | (26.67%) |
| FY2024 | $0.30 | (60.00%) |
| FY2023 | $0.75 | 15.38% |
| FY2022 | $0.65 | (42.48%) |
| FY2021 | $1.13 | 769.23% |
| FY2020 | $0.13 | (74.51%) |
| FY2019 | $0.51 | (52.34%) |
| FY2018 | $1.07 | 57.35% |
| FY2017 | $0.68 | 61.90% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | $0.22 | (18.52%) |
| Jun 2025 | $0.27 | 42.11% |
| Jun 2024 | $0.19 | — |
| Mar 2024 | −$0.02 | — |
| 25 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| UTHR United Therapeutics Corporation compare | $26.50 |
| NBIX Neurocrine Biosciences, Inc. compare | $6.74 |
| ZTS Zoetis Inc. compare | $6.07 |
| TAK Takeda Pharmaceutical Co. | $0.66 |
| HLN Haleon PLC Sponsored ADR compare | $0.45 |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $0.43 |
| RDY Dr. Reddy's Laboratories Ltd compare | $0.33 |
| ELAN Elanco Animal Health Incorporated compare | −$0.41 |
| VTRS Viatris Inc. compare | −$0.53 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on TAK
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement